Cencora, Inc. COR
348.71 USD +2.95 (+0.85%)
At closeNov 11, 2026, 4:06 AM EST
346.51 -2.20 -0.63%
Pre-market · Nov 11, 4:06 AM ET
342.60 Day range 350.17
244.82 52-week range 377.54
- YTD
- +3.25%
- 1 year
- -4.37%
News
benzinga.com JP Morgan Maintains Overweight on Cencora, Raises Price Target to $413 JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $390 to $413.
seekingalpha.com Dividend Announcements: October 31-November 6, 2026 (Part 2 Of 2) I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. In this second article in two parts,…
benzinga.com Here’s How Much You Would Have Made Owning Cencora Stock In The Last 10 Years Cencora (NYSE:COR) has outperformed the market over the past 10 years by 7.95% on an annualized basis producing an average annual return of 20.98%. Currently, Cencora has a market capitalization of…
zacks.com 3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
benzinga.com Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $405 Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $388 to $405.
benzinga.com Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $380 Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $350 to $380.
marketbeat.com What Cencora (COR) Said on Its Q4 Earnings Call Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a…
zacks.com Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
seekingalpha.com Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
zacks.com Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Cencora Q4 2026 Earnings Call Transcript Cencora (NYSE:COR) reported fourth-quarter financial results on Wednesday. The transcript from the company’s fourth-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates Cencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.
benzinga.com Cencora Increases Quarterly Dividend From $0.60 To $0.66 Per Share; Announces Corporate Realignment To Separate Out Specialty Solutions On November 3, 2026, the Company declared a quarterly dividend of $0.66 per common share, a 10 percent increase in its quarterly dividend rate from $0.60 per common share. The quarterly dividend of…- benzinga.com Cencora Sees FY2027 Adj EPS $19.40-$19.75 vs $19.70 Est; Sees Sales $347.519B-$354.267B vs $352.380B Est Cencora (NYSE:COR) is looking for FY2027 Adj EPS of $19.40-$19.75 vs $19.70 analyst estimate. sees sales of $347.519 billion-$354.267 billion vs $352.380 billion analyst estimate.
businesswire.com Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion.…
businesswire.com Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…- benzinga.com Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $377 Morgan Stanley analyst Erin Wright maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $346 to $377.
- benzinga.com Baird Maintains Outperform on Cencora, Raises Price Target to $375 Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $373 to $375.
benzinga.com Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years Cencora (NYSE:COR) has outperformed the market over the past 5 years by 11.54% on an annualized basis producing an average annual return of 22.6%. Currently, Cencora has a market capitalization of…
benzinga.com Cencora Agrees To Acquire Remaining Stake In American Oncology Network For $2.4B Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX:AONC), a physician-led network of more than 350 oncology…
benzinga.com Argus Research Maintains Buy on Cencora, Raises Price Target to $380 Argus Research analyst David Toung maintains Cencora (NYSE:COR) with a Buy and raises the price target from $340 to $380.
finance.yahoo.com Newsmax, Inc. (NMAX) Stock Price, News, Quote & History - Yahoo Finance The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for…eu.36kr.com Anfu, Dongshan and Fosun have all followed suit, but why can't China develop its own Berkshire Hathaway? Against the backdrop of a cooling AI hype cycle, "At the Ebb of the AI Tide: Insights from an Old Machine" delivers unique, ...
- 247wallst.com Cencora Inc Looking ahead to 2030, our model projects COR could trade at an average price of $526.61, with a potential range between $394.96 and $658.26. This represents a potential 57.9% return from today’s ...
finance.yahoo.com 3D Construction Market Size, Share, Industry Trends, and Growth Forecasts, 2026-2031 | Market to Reach USD 20.78 Billion as Automation and Affordable Housing Drive 35.45% CAGR Public funding, faster builds, leaner crews, less waste and AI quality control strengthen 3D construction ROI, while mortgage access and prefabrication support scale.Dublin, Nov. 10, 2026 (GLOBE ...finance.yahoo.com Can Cardinal Health Stock Repeat Its Last Five Years? Cardinal Health (CAH) operates as a drug distributor whose largest customer is CVS Health, while also selling its own ...
- finance.yahoo.com 5 insightful analyst questions from Calumet’s Q3 2026 earnings call Calumet delivered above-consensus top- and bottom-line results in the third quarter, but the market reacted negatively, reflecting investor concerns about margin compression and sustainability of ...
marketscreener.com JPMorgan Adjusts Price Target on Cencora to $413 From $390 Cencora to acquire American Oncology Network in $2.4 billion deal RE Cencora, Inc. specializes in distributing pharmaceutical ...
msn.com First look: Leatt SuperTack flat pedal MTB shoes We take a look at the complete refresh of Leatt's flat pedal shoe offerings, now with a better fit and insane amounts of grip ...
- tipranks.com Worksport Reports Record Third-Quarter Sales and Narrower Loss Worksport ( ($WKSP) ) has shared an announcement. On November 10, 2026, Worksport reported results for the third quarter ended September 30, 2026, with record net ...
ad-hoc-news.de Cencora stock enters fiscal 2027 with specialty-led growth outlook Cencora stock enters fiscal 2027 with a specialty-led growth plan and a new reporting structure. The company also raised its ...
kalkine.com.au Pilot Energy Administrators Secure Further Convening Period Extension to 3 February 2027 Pilot Energy (ASX:PGY) administrators Jeremy Nipps, Stephen Earel and Darryl Kirk of Cor Cordis have secured a further ...
- msn.com The Kiplinger Dividend 15: Our favorite dividend-paying stocks Rising interest rates create a risk for The Kiplinger Dividend 15, but our favorite dividend-paying stocks remain a worthy consideration for most portfolios.